Long-Acting Amylin Analogue for Appetite Regulation, Metabolic Health & Weight Management Research

What Is Cagrilintide?

Cagrilintide is a long-acting synthetic analogue of amylin, a naturally occurring peptide hormone that is co-secreted with insulin from pancreatic β-cells following meals.

While GLP-1 has become well known for appetite regulation, amylin represents an entirely different metabolic signaling pathway. Amylin communicates satiety signals to the brain, helping regulate food intake, gastric emptying, glucagon secretion, and overall energy balance. Cagrilintide was engineered to provide prolonged activation of these pathways through once-weekly administration.

Unlike GLP-1 receptor agonists, Cagrilintide primarily acts through amylin receptors (AMYRs) and calcitonin receptor complexes within the central nervous system. Because these pathways are complementary rather than redundant, Cagrilintide has become an important area of research both as a stand-alone therapy and in combination with GLP-1 agonists such as semaglutide.

What Does It Do?

Cagrilintide is being investigated for its ability to support:

• Appetite regulation and increased satiety

• Reduced caloric intake

• Healthy body weight management

• Improved metabolic flexibility

• Delayed gastric emptying

• Reduced post-meal glucagon secretion

• Improved glycemic control

• Long-term weight maintenance

Rather than increasing metabolism directly, Cagrilintide primarily helps regulate the body’s natural fullness signaling, allowing many individuals to feel satisfied with less food.

How Does It Function in the Body?

1. Mimics the Natural Hormone Amylin

After eating, pancreatic β-cells normally release:

• Insulin

• Amylin

While insulin regulates blood glucose, amylin tells the brain:

“You’ve eaten enough.”

Cagrilintide replaces and amplifies this physiologic satiety signal through a long-acting analogue designed for sustained receptor activation.

2. Activates Amylin Receptors

Cagrilintide binds to amylin receptor complexes (AMYRs) located primarily within the area postrema and nucleus tractus solitarius of the brainstem.

Activation of these receptors:

• Increases satiety

• Reduces hunger

• Decreases food reward signaling

• Lowers overall caloric intake

Unlike stimulant-based appetite suppressants, this mechanism works through the body’s endogenous meal termination pathways.

3. Slows Gastric Emptying

Amylin signaling naturally delays the movement of food from the stomach into the small intestine.

This contributes to:

• Longer-lasting fullness

• Reduced post-meal glucose excursions

• More gradual nutrient absorption

These effects complement appetite regulation while helping improve postprandial metabolic control.

4. Suppresses Postprandial Glucagon

Cagrilintide also helps reduce excessive glucagon secretion after meals.

By moderating glucagon release, research suggests it may support:

• Improved glucose regulation

• Reduced hepatic glucose production

• Healthier metabolic homeostasis

This mechanism complements insulin activity without directly replacing it.

What Do Studies Show?

Clinical and preclinical research has demonstrated promising results for Cagrilintide in obesity and metabolic disease.

Studies have reported:

• Clinically significant, dose-dependent reductions in body weight and waist circumference in adults with overweight and obesity receiving once-weekly Cagrilintide.
• Greater weight loss with higher doses of Cagrilintide compared with placebo, and in one phase 2 trial, greater reductions than liraglutide 3.0 mg.
• Activation of amylin receptors in brain regions involved in appetite regulation, leading to reduced food intake through homeostatic and reward pathways.
• Additive effects when combined with GLP-1 receptor agonists, reflecting complementary mechanisms that influence appetite, gastric emptying, glucagon secretion, and energy balance.
• A generally favorable tolerability profile in clinical trials, with gastrointestinal symptoms (such as nausea) being the most commonly reported adverse effects during dose escalation.

Overall Functions

Based on current research, Cagrilintide is commonly investigated to support:

✓ Increased satiety

✓ Reduced appetite

✓ Lower caloric intake

✓ Healthy body weight management

✓ Improved metabolic control

✓ Better post-meal glucose regulation

✓ Long-term weight maintenance

✓ Synergistic metabolic support when combined with GLP-1 therapies

Cagrilintide fits naturally within your Metabolic Optimization category and complements the other metabolic peptides you already offer.

Potential complementary pairings:

• Retatrutide → Triple-hormone metabolic signaling (GLP-1/GIP/Glucagon)
• Tesamorelin → Body composition and visceral fat support
• MOTS-c → Mitochondrial energy metabolism and insulin sensitivity
• NAD⁺ → Cellular energy production and metabolic resilience

REFERENCES:

ou could include these as your featured references:

1. Lau DCW, et al. Once-weekly Cagrilintide for Weight Management in People with Overweight and Obesity. The Lancet. 2021.
   https://pubmed.ncbi.nlm.nih.gov/34798060/
2. Gadde KM, Allison DB. Long-Acting Amylin Analogue for Weight Reduction. The Lancet. 2021.
   https://pubmed.ncbi.nlm.nih.gov/34798059/
3. Sattar N, et al. New Therapies for Obesity. Cardiovascular Research. 2023.
   https://academic.oup.com/cardiovascres/article/119/18/2825/6854907
4. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. 2021.
   https://doi.org/10.1021/acs.jmedchem.1c00565
5. Cao J, et al. Structural and Dynamic Features of Cagrilintide Binding to Calcitonin and Amylin Receptors. Nature Communications. 2025.
   https://www.nature.com/articles/s41467-025-58680-y